TPO and autoimmune thrombocytopenic purpura: However, we considered that the American guidelines for ITP [5] recommend only splenectomy, TPO-RAs and rituximab as second-line treatment options, and TPO-RAs represent the only third-line treatment option covered by medical insurance in the Japanese guidelines.